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Background: Heparin-induced thrombocytopenia (HIT) causes thromboembolic complications which threaten
life and limb. Heparin is administered to virtually every critically ill patient as a protective measure against
thromboembolism. Argatroban is a promising alternative anticoagulant agent. However, a safe dose which still
provides effective thromboembolic prophylaxis without major bleeding still needs to be identified.
Methods: Critically ill patients (n = 42) diagnosed with HIT at a tertiary medical center intensive care unit from 2005
to 2010 were included in this retrospective analysis. Patient records were perused for preexisting history of HIT,
heparin dosage before HIT, argatroban dosage, number of transfusions required, thromboembolic complications
and length of ICU stay (ICU LOS). Patients were allocated to Simplified Acute Physiology Scores above and below
30 (SAPS >30, SAPS <30), respectively. For calculations, patients (n = 19) without previous history of HIT were
compared to patients (n = 23) with a history of HIT before initiation of argatroban.
Results: The mean initial argatroban dosage was below 0.4 mcg/kg/min regardless of SAPS score. Maintenance
dosage had to be increased in patients with SAPS <30 to 0.54 ± 0.248 mcg/kg/min (p >0.05) to achieve effective
anticoagulation. No thromboembolic complications were encountered. Argatroban had to be discontinued
temporarily in 16 patients for a total of 57 times due to diagnostic or surgical procedures, supratherapeutic aPTT
and bleeding without increasing the number of transfusions. A history of HIT was associated with a shorter ICU LOS
and significantly reduced transfusion need when compared to patients with no history of HIT. Cost calculation
favour argatroban due to increased transfusion needs during heparin administration and increase ICU LOS.
Conclusion: Argatroban can be used at doses < 0.4 mcg/kg/min without an increase in transfusion requirements
and at a reduced overall treatment cost compared to heparin.
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In heparin-induced thrombocytopenia (HIT) immuno-
globulin G is formed against multimolecular complexes of
platelet factor 4 (PF4) and polyanion heparin, which poten-
tially leads to thromboembolic life and limb threatening
complications [1,2]. Clinical diagnosis is based on the 4 T
score (Thrombocytopenia, Timing, Thrombosis, absence
of other explanations) [3,4]. Typically, clinical suspicion* Correspondence: Se-Chan.Kim@ukb.uni-bonn.de
†Equal contributors
Department of Anesthesiology and Intensive Care Medicine, University
Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany
© 2015 Kim et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.of HIT is made by a platelet count drop in the 5–10
days following heparin administration. However, it should
be kept in mind that in almost 60% of patients diagnosed
with HIT, thrombosis occurs prior to or on the day of
significant platelet decrease [5]. Differential diagnoses
include EDTA-induced pseudothrombocytopenia, non-
immune heparin-associated thrombocytopenia, throm-
botic-thrombocytopenic purpura, other drug-induced
thrombocytopenias, disseminated intravascular coagulation,
acute thrombosis-associated thrombocytopenia and sepsis
[6]. Guideline recommendations consist of discontinuation
of all heparin, initiation of a non-heparin anticoagulant dueis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing diagnosis with a serologic assay [7]. PF4 enzyme linked
immunosorbent assay (ELISA) detects immunoglobulin G
antibodies and is a widely used initial assay. However, this
test has poor specificity, which might lead to overdiagnosis
and overtreatment of HIT, including increased risk of
bleeding [8,9]. Furthermore, costs of alternative anticoagu-
lants imply an additional economic burden [10]. Only a
subset of anti-PF4/heparin antibodies activate platelets,
which makes certain platelet activation assays, such as the
heparin-induced platelet activation assay (HIPAA) and the
serotonin release assay (SRA), more specific. However,
HIPAA and SRA are restricted to specialized laboratories.
Diagnosing HIT in critically ill patients is difficult due to
the high incidence of thrombocytopenia in this patient
population. The incidence varies and seems to be higher
among surgical patients compared to non-surgical patients
[11,12].
Argatroban is a direct thrombin inhibitor and is used as
an alternative anticoagulation agent in HIT. An initial dos-
age of 2 mcg/kg/min without a bolus is recommended ex-
cept for patients with heart failure, liver dysfunction,
multiorgan dysfunction syndrome, severe anasarca and
early post-cardiac surgery phase. A dose reduction to 0.5 -
1.2 mcg/kg/min is recommended in this patient popula-
tion, according to the manufacturer. Argatroban follows
hepatobiliary elimination. Hence it is the preferred agent
in patient in renal failure. But it needs to be closely moni-
tored and dosage must be adjusted in case of hepatic in-
sufficiency [13]. However, the optimal dosage for critically
ill patients is still under investigation [14-17]. Even recom-
mended dosages for critically ill patients could lead to
blood loss [18]. The aim of this retrospective study was to
evaluate the safety of argatroban dosage in critically ill pa-
tients, operationalized as number of thromboembolic
events (i.e., myocardial infarction, stroke, pulmonary em-
bolism and peripheral arterial occlusion), increased bleed-
ing and need for blood transfusions, as well as mortality
and length of ICU stay (ICU LOS). In addition, we com-




Ethical approval for this study (Ethical Committee
N° 061/14) was provided by the Ethical Committee Bonn
University Hospital, Bonn, Germany (Chairperson Prof.
K. Racké) on 26th February 2014. Informed consent was
waived and data were analyzed anonymously.
Patients
This retrospective study included 42 patients (18 female/
24 male) in a six year period (2005–2010) who were diag-
nosed with HIT before or during admission to the ICUand received argatroban during their stay at the surgical
ICU at the University Hospital of Bonn, Germany, a ter-
tiary care academic medical center. Initial and mainten-
ance dosage of argatroban and transfusion requirements
in these patients were evaluated to assess safe dose ranges
for argatroban. Critically ill patients were allocated to Sim-
plified Acute Physiology Score (SAPS) of above 30 (>30)
and below 30 (<30) at the time of ICU admission. Changes
in SAPS score were documented daily and correlated with
argatroban dose. Clinical suspicion of HIT was made if pa-
tients had a new onset of thrombocytopenia, recent hep-
arin exposure and/or thromboembolic complications
followed by PF4 ELISA. Patients with PF4 ≥ 0.4 OD were
defined as HIT positive. Confirmatory HIPAA was add-
itionally performed. Platelet recovery following initiation
of argatroban therapy served as a clinical parameter to
confirm diagnosis of HIT. Patients´ data and laboratory
values were extracted from hospital records and the clin-
ical information system. According to the department´s
policy, heparin exposure (e.g. intravenous administration)
was discontinued and catheters filled with heparinized so-
lutions were exchanged as soon as clinical suspicion of
HIT was raised, while awaiting a confirmatory diagnostic
testing. Initial dosage was at the discretion of the respon-
sible physician. One patient received lepirudin before
argatroban and one patient danaparoid after argatroban. A
third patient received a single oral medication of 100 mg
aspirin. The argatroban dosage was adjusted for a target
activated partial thromboplastin time (aPTT) 1.5 to 3
times that of the baseline aPTT. The aPTT was routinely
monitored twice daily and 4 hrs after dosing changes per
ICU policy. Bleeding was assessed by hemoglobin fall and
transfusion monitoring of packed red blood cells (PRBC),
fresh frozen plasma (FFP) and platelets (i.e., ≧ 2 PRBC in
24 hours and/or a fall in hemoglobin ≧ 2 g/dL). Recog-
nition and diagnosis of thromboembolic complications
(e.g., myocardial infarction, stroke, pulmonary embolism
and peripheral arterial occlusion) were included in the
daily intensive care routine. Renal function was evaluated
with serum creatinine, blood urea nitrogen (BUN) and
creatinine clearance. Acute kidney failure was treated with
continuous renal replacement therapy (CRRT). Liver func-
tion tests included bilirubin, liver enzymes (alanine/as-
partate aminotransferase (ALT/AST), gamma-glutamyl
transferase (GT)) and albumin. Moderate elevation of
serum aminotransferase was defined by more than 3 times
the upper limit of normal [19]. Respiratory failure was
defined as PaO2/FiO2 < 200 mmHg [20]. Furthermore we
compared ICU LOS and transfusion requirements for
patients with a history of HIT with those patients who
received heparin shortly before HIT was suspected (no
history of HIT) and argatroban was initiated. The results
were used for cost calculations of argatroban versus hep-
arin administration. Calculations were based on current
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188.12 EUR for 250 mg argatroban. The investigated para-
meters comprised total daily anticoagulant administration,
duration of heparin administration before initiation of arga-
troban, blood transfusion and ICU LOS were incorporated
in the total cost calculation.
Statistical analysis
All data are reported in mean ± standard error of the
mean (SEM). A Student t- test or a Mann–Whitney U
test was performed where appropriate. Significant differ-
ences were considered to exist at p < 0.05.
Results
Patients´ demographics are summarized in Table 1.
Diagnosis of HIT
Argatroban was initiated in all patients with a history of
HIT and suspected HIT which was clinically diagnosed
by a history of heparin exposure and thrombocytopenia
based on the 4 T score [3,4]. Anticoagulation was initi-
ated when there was no clinical sign of perioperative
bleeding and aPTT was in the lower reference range.
The average time elapsed from time of ICU admission
to starting anticoagulation was 13.22 ± 4.24 hours for
patients with a history of HIT and 8.25 ± 3.28 hours in
patients without a history of HIT (p > 0.05). While 23
(54.8%) patients had a history of HIT, 19 patients
(45.2%) with no history of HIT had received heparin for
7.5 ± 1.3 days before HIT was suspected. Exposure to
heparin was found in 17 (85%) patients (906.4 ±
186.5 IE/h) up to the day before initiation of argatroban.
In the remaining 2 patients, heparin infusion was
interrupted more than 24 hours before initiation ofTable 1 Demographic data (mean ± SEM, n = 42, except
when marked otherwise)
Age (years) 61 ± 2.4
Body weight (kg) 84.4 ± 3.2
Body Mass Index kg/m2 29.2 ± 1.2
Length of ICU-Stay (days) 15 ± 2.9
history of HIT 6.0 ± 1.2, n = 23
no history of HIT 25.8 ± 5.0, n = 19
SAPS <30 11 ± 3.0, n = 16
SAPS >30 18 ± 4.2, n = 26
SAPS score on ICU admission 34 ± 2.2
Sepsis 14 (33%)
Renal replacement therapy 17 (40.5%)
Respiratory failure 31 (73.8%)
Veno-arterial ECMO 1 (2.4%)
Death* 6 (14.2%)
*Death was unrelated to bleeding, thromboembolic complication or argatroban.argatroban. Based on the 4 T score, there was a high
probability (4 T = 6-8) of HIT in 4 (21.1%) patients with
no history of HIT, intermediate (4 T = 4-5) in 10 (52.6%)
and low probability (4 T≦3) in 5 patients (26.3%). In
patients with no history of HIT, PF4 ELISA was positive
in 17 cases (94.4%) out of 18 tested patients. In all 5
patients with low HIT probability score, PF4 ELISA and
HIPAA were positive, respectively. Mean platelet count
was 148.6 ± 19.58 G/L at time of ICU admission.
Bleeding and thromboembolic complications
The initial dosage of argatroban anticoagulation was
0.37 ± 0.069 mcg/kg/min in SAPS >30 and 0.35 ± 0.103
mcg/kg/min in SAPS <30 (Figure 1). Maintenance dos-
age was slightly reduced in SAPS >30 to 0.32 ± 0.067
mcg/kg/min to achieve aPTT-prolongation 1.5 to 3
times of the baseline. In SAPS <30, maintenance dosage
was increased to 0.54 ± 0.248 mcg/kg/min to achieve
effective anticoagulation (Figure 1, p > 0.05). The initial
dosage in our study was below the manufacturer’s rec-
ommendations for critically ill patients with organ failure
and patients with cardiac surgery (0.5 - 1.2 mcg/kg/min).
There was no correlation between initial dosage (r =
− 0.073) or maintenance dosage adjustment (r = − 0.326)
and change in SAPS scores. Duration of argatroban ther-
apy was 8.4 ± 2.11 days. Effective anticoagulation was
monitored with aPTT which was prolonged 1.25-fold by
8.38 ± 2.0 s as compared with a mean aPTT prior to arga-
troban (45.12 ± 2.00 s, n = 41 vs. 36.02 ± 1.52 s, n = 32;
p = <0.001). According to local hospital guidelines, antic-
oagulation for thromboembolic prophylaxis was efficient
with an aPTT in the range of 35 to 40 s. In ten patients
with a history of HIT, a baseline aPTT was not available
before initiation of argatroban anticoagulation. None
of the study patients developed a newly diagnosedFigure 1 Initial - and maintenance dosage (mean ± SEM) of
argatroban (mcg/kg/min) in critically ill patients depending on
SAPS-score. n = 42, p < 0.05.
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bleeding was defined by a hemoglobin fall ≧ 2 g/dL and
a transfusion of ≧ 2 PRBCs within 24 h. Argatroban
infusion was discontinued temporarily in 16 patients
for a total of 57 times. Reasons for discontinuation in-
cluded diagnostic or surgical procedures (20/57; 35.1%),
supratherapeutic aPTT (14/57; 24.6%) and bleeding
(12/57; 21.1%). Hence, with this management and mon-
itoring, red blood cell transfusion under argatroban
therapy was not increased (Figure 2A and 2B, p > 0.05).
Transfusions of fresh frozen plasma and platelets were
not significantly affected by argatroban therapy.Elevated serum aminotransferases and argatroban
Moderate elevated serum aminotransferases (>3 times of
the upper limit of normal) and increased total bilirubin
were found in seven of the investigated patients. Initial
dosage in these patients was slightly higher (0.40 ± 0.14
mcg/kg/min, n = 7) than in patients with normal hepatic
parameters (0.36 ± 0.06 mcg/kg/min, n = 35; p = 0.7752).
However, the initial dosage was slightly below the rec-
ommendation of 0.5 mcg/kg/min in patients with liver
dysfunction (Child Pugh Class B). There was no differ-
ence in maintenance dosage during the rest of the ICU
stay (0.42 ± 0.09 mcg/kg/min, n = 7 vs. 0.40 ± 0.12 mcg/
kg/min, n = 35; p = 0.9490). In three patients with mod-
erate elevated aminotransferases, argatroban therapy had
to be discontinued due to hemoglobin fall or supratherapeutic
aPTT. In these patients duration of discontinuation was
disproportionately higher: 63.3% of the total interruption
time was due to a fall in hemoglobin > 2 g/dL; 49.1%
of total time of interruption in all patients due to
supratherapeutic aPTT. Although, overall transfusion ofFigure 2 Red blood cell transfusion under argatroban. PRBC transfusio
before and during argatroban therapy during ICU stay. p < 0.05.blood components was unaffected by argatroban therapy
in patients with moderate elevated aminotransferases, this
data suggests a higher bleeding tendency in patients with
moderate elevated aminotransferases.Impact of history of HIT
There was a significant shorter length of stay in the ICU
for patients with a history of HIT (6.0 ± 1.2 days, n = 23)
compared to patients with no history of HIT (25.8 ±
5.0 days, n = 19; p < 0.001, Table 1, Figure 3A). Patients
with no history of HIT had a slightly but not significantly
higher SAPS-score (30.8 ± 2.7, n = 23 vs. 37.3 ± 3.5, n = 19;
p = 0.1459, Figure 3B). ICU LOS was 7.5 ± 1.3 days before
HIT diagnosis was established. Patients with a history of
HIT received argatroban 13.22 ± 4.24 hours after admission
to the ICU. Red blood cell transfusion was significantly less
in patients with a history of HIT (4.4 ± 2.8 PRBC) before
initiation of argatroban when compared with transfusion
need of patients with no history of HIT (9.9 ± 3.6 PRBC)
(Figure 4, p < 0.05). For FFP no statistical difference was
found (Figure 5). Platelet transfusion was significantly lower
during argatroban therapy in patients with a history of HIT
(0.2 ± 0.1 platelet units) than in patients with no history of
HIT (2.3 ± 1.3 platelet units) (Figure 6, p < 0.05).Cost calculations
Patients (n = 19) receiving heparin before HIT was sus-
pected served as a comparison group for cost calculation
of argatroban versus heparin administration. In this study
population the mean dosage for heparin was 906.4 ±
186.5 IE/h or 21744 IE/d (n = 19), whereas the mainten-
ance dosage of argatroban was 0.41 ± 0.10 mcg/kg/min
(n = 42) or 49.6 mg/d (0.41 mcg × 84 kg × 1440 min).n (mean ± SEM) in patients with (A) SAPS <30 and (B) SAPS >30
Figure 3 Length of ICU stay and SAPS-score dependent of history of HIT. A) ICU LOS and B) SAPS-score in patients with (n = 23) and
without a history of HIT (n = 19). *p < 0.05.
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EUR for 25.000 IE heparin compared to 188.12 EUR for
250 mg (37.6 EUR per 50 mg) argatroban, the costs per
day are about 17 times higher for argatroban administra-
tion than they are for heparin. In patients with no history
of HIT, thus receiving heparin, transfusion requirements
were higher than for patient with a history of HIT before
initiation of argatroban therapy (4.4 ± 2.8 PRBC, n = 14 vs.
9.9 ± 3.6 PRBC, n = 18). Considering a PRBC unit price of
90 EUR, total costs for PRBC of 900 EUR for patients with
no history of HIT under heparin versus 450 EUR for pa-
tients with a history of HIT have to be calculated. Patients
had a mean ICU LOS of 7.5 ± 1.3 days before HIT suspi-
cion was made. Assuming that these patients would haveFigure 4 PRBC before and during argatroban therapy in patients
with and without a history of HIT. * p < 0.05.received argatroban in the first place instead of heparin,
we estimate a total sum of 283.88 EUR for argatroban with
a daily cost calculation of 37.60 EUR/d for argatroban
multiplied with 7.5 days ICU LOS. This should be com-
pared to 450 EUR additional costs for PRBC transfusions
during heparin administration. Additional costs for la-
boratory testing (PF4 ELISA = 27.98 EUR, HIPAA= 52.46
EUR) would add up to a total of 364.32 EUR (Table 2).
Furthermore, patients with a history of HIT had a
significant shorter ICU LOS. Assuming average costs of
1050.00 EUR per ICU day, total costs of ICU care in
patients with a history of HIT would be 6 days × 1050
EUR = 6300 EUR versus 26 days × 1050 EUR = 27300
EUR in patients with no history of HIT, respectivelyFigure 5 Fresh frozen plasma (FFP) units consumption (mean ±
SEM) before and during argatroban therapy in patients with
known and unknown HIT. p < 0.05.
Figure 6 Platelet units before and during argatroban therapy
in patients with and without a history of HIT. *p < 0.05.
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tory of HIT (Table 2).
Discussion
The primary aims of this study were to investigate the safe
dosage of argatroban in critically ill patients, thrombo-
embolic complications and use of blood components. Fur-
thermore, we analyzed the impact of a history of HIT on
ICU LOS and the need for blood transfusions and the
resulting economic consequences of argatroban versus
heparin administration.
One striking finding of our study was that in our in-
vestigated population patients with a history of HIT hadTable 2 Comparison of costs for heparin versus argatroban
Heparin Argatroban
Mean dosage/ICU day 21744 IE 49.6 mg
Costs/ICU day 2.17 EUR 37.60 EUR
Total costs before HIT
(mean ICU LOS before HIT
suspicion = 7.5 days)
16.40 EUR 283.90 EUR




9.9 units 4.4 units
PRBC total costs before
HIT (unit costs = 90 EUR)
900.00 EUR 450.00 EUR
Total costs for anticoagulation
and transfusions
916.40 EUR 814.34 EUR
ICU LOS 26 6
Total costs of ICU stay
(1050EUR/day)
27.000.00 EUR 6.300.00 EUR
An ICU LOS of 7.5 days and increased RBC transfusion with heparin anticoagulation
were assumed. For further details see text.a much shorter ICU LOS when compared to patients
with no history of HIT, regardless of SAPS score. The
reason for a longer ICU LOS remains unclear. Patients
with no history of HIT develop thrombocytopenia during
their ICU stay because heparin is usually administered
perioperatively. Thrombocytopenia itself is not a reason
for an extended ICU stay. However, once suspicion of
HIT arises, patients are closely monitored for thrombo-
embolic events and argatroban therapy, which can be best
established in the ICU. Red blood cell transfusion need
was lower in patients with a history of HIT before anticoa-
gulation with argatroban compared with patients with no
history of HIT. There was also a difference for FFP and
platelet transfusion, but the differences did not reach stat-
istical significance. Platelet transfusions were less frequent
in patient with a history of HIT during argatroban ther-
apy. These findings imply that patients with no history of
HIT are more prone to bleeding and have greater transfu-
sion needs due to inadequate anticoagulation with heparin
and thrombocytopenia. A recent study by Williamson
et al. demonstrated that critically ill patients with
thrombocytopenia have a higher risk of bleeding with
subsequent transfusion need and increased ICU and
hospital mortality [21]. The reported incidence of HIT
is 0.3% in perioperative patients and associated with a
50% increased mortality [22]. Clinical development and
suspicion of HIT, which is based mainly on significant
thrombocytopenia, is usually established over the course of
a couple of days. Once HIT is suspected, argatroban ther-
apy is initiated. It has to be taken into consideration that
platelet count may further decrease and thromboembolic
complications may have already developed [5]. This may
also affect transfusion needs during the remaining course
of the ICU stay. In contrast, early screening of patients for
HIT with a PF4 ELISA on admission to the ICU leads to
overdiagnosis of HIT since it remains a clinical diagnosis
[9]. Although a safety profile of argatroban in critically ill
patients still needs to be established, bleeding complica-
tions are also common in patients on heparin [23]. Consid-
ering the fatality of thromboembolic complications due to
HIT, general use of argatroban could be favorable. Further-
more, laboratory screening tests for HIT would be redun-
dant if agratroban were be used in the first place.
Our retrospective analysis confirmed the current prac-
tice that the dosage should not be higher than 0.5 mcg/
kg/min in critically ill patients, as recommended by the
manufacturer. Moreover, a dosage below 0.4 mcg/kg/min
can be considered safe in terms of thromboembolic
events. Link et al. postulated a dosage calculation for arga-
troban in critically ill patients needing continuous renal
replacement therapy using ICU scores such as APACHEII
and SAPSII. A dose range of 0.5-1.2 mcg/kg/min would
correspond to SAPS scores 30–52 according to a pre-
dicted dosage calculation [13]. In our patient population
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and SAPS scores. Maintenance dosage had to be slightly
increased in SAPS <30 to achieve aPTT with 1.5 to 3-fold
of baseline range. A SAPS score of 31 is consistent with
severe illness and correlates with a predicted mortality of
11.7% [24,25]. In SAPS >30 critically ill patients in this
study population, maintenance dosage was unchanged
when compared to initial dosage. In the past, studies in
critically ill patients have defined an argatroban dose range
of lower than 0.5 mcg/kg/min [16,26,27]. These low dos-
ages are not only safer for patients in terms of bleeding
complications but are also more cost-effective for both
blood component and argatroban consumption.
For economic considerations and cost calculations, pa-
tients with no history of HIT who received heparin be-
fore HIT suspicion was raised served as a comparison
group. Although costs of argatroban administration were
17 times higher per day compared to heparin adminis-
tration, these costs would be compensated by a reduced
need for transfusions if argatroban was used as a first
line anticoagulant in patients with no history of HIT.
Interestingly, patients with no history of HIT had a sig-
nificantly longer ICU LOS, which ultimately accounts
for higher total costs for intensive care. Considering the
devastating thromboembolic complications in 30% of
cases associated with HIT, mortality rates up to 20%
[28], an average cost-of-illness for confirmed HIT with
thrombosis of 34155 Canadian Dollars (=22432 EUR/
30847 USD in 2014) [29] and an incidence of up to 5%
[30], alternative anticoagulants such as argatroban could
have a better economic profile than heparin itself, des-
pite argatroban’s higher market price.
As with all anticoagulants, major bleeding is one of
the most common adverse events of argatroban therapy,
but compared to a historical control bleeding complica-
tions are not increased [18,31]. Hepatic dysfunction and
critical illness warrant dose adjustment as demonstrated
by previous studies [16,27]. Doepker and coworkers
identified argatroban-associated bleeding risk factors
such as bilirubin >3 mg/dL, platelets <70 K/mcL and ini-
tial dosing body weight >90 kg [18]. Starting dose ranges
vary between 0.2 mcg/kg/min in Beiderlinden’s study
and 0.56 mcg/kg/min in Doepker’s study. Kiser et al. in-
vestigated a fixed dosage adjustment protocol to achieve
a target aPTT. Although, their data suggest that 78% of
their patient population was located in the ICU and had
a dose regimen based on organ dysfunction, the mean
initial dosage for argatroban was 1.5 mcg/kg/min and 1.3
mcg/kg/min for maintenance [32]. In the present retro-
spective study, we analyzed the safety of the dose ranges
of argatroban administered to critically ill patients by
assessing the need of transfusions before and during arga-
troban therapy. The overall need for blood component
transfusions during argatroban therapy during ICU staywas not increased when compared with transfusion need
before initiation of argatroban. However, argatroban ther-
apy was temporarily discontinued when a major bleeding
event occurred, during diagnostic and interventional pro-
cedures and with a supratherapeutic aPTT. While aPTT is
the anticoagulation monitoring of choice for argatroban,
incorporation in the daily ICU routine for HIT patients
may be challenging due to multiple interruptions of ther-
apy due to diagnostic or interventional procedures. Rota-
tional thrombelastometry (ROTEM) evaluated in vitro
shows a strong correlation between clotting time and
aPTT. It could be a potential alternative for bedside
monitoring of argatroban therapy [33]. However, major
bleeding during argatroban therapy may still occur des-
pite low dose regimen. Specifically, hepatic dysfunction
(Child-Pugh class B) warrants dose reduction, since arga-
troban is metabolized in the liver by hydroxylation and
aromatization of the 3-methyltetrahydroxyquinoline ring.
In our study population, seven patients were identified
with moderately elevated serum aminotransferases. Arga-
troban initial and maintenance dosage were below the
manufacturer’s recommended dosage of 0.5 mcg/kg/min
and did not differ when compared with all other study
patients. Furthermore, the number of blood transfusions
was not increased. However, argatroban therapy in patients
with elevated aminotransferases had to be interrupted
more often and for longer time intervals compared to all
other patients. No thromboembolic complications were
encountered in our patient population.
This study has some limitations. A heterogeneous
surgical population was investigated in this retrospective
analysis. Thus, bleeding risk factors are difficult to evalu-
ate and argatroban therapy could have varying effects on
overall bleeding. APTT and interruption of argatroban
may not reflect a direct anticoagulatory effect of argatro-
ban. Minimum aPTT range to prevent thrombembolic
complications under argatroban was not evaluated. Fur-
thermore, this study lacks a historical control group due
to heterogeneity of the investigated patients. However, it
was not the aim of this study to directly compare argatro-
ban with heparin in terms of bleeding risk. We compared
parameters before and after argatroban in patients who
had no history of HIT, thus receiving heparin before HIT
was suspected. The transfusion requirement data was not
corrected for the time before initiation of argatroban. It
has to be considered that this comparison group had a
higher risk of bleeding with respect to HIT while heparin
was still administered requiring more PRBC transfusions.
Conclusion
Low dosage of argatroban for critically ill patients is safe
with respect to thromboembolic complications. Clinical
monitoring of bleeding in the surgical population
remains the most important parameter for adequate
Kim et al. Journal of Cardiothoracic Surgery  (2015) 10:19 Page 8 of 8argatroban dosing while close aPTT monitoring remains
a challenge for the daily ICU routine. Our data suggests
that patients with new onset of HIT have an overall longer
ICU stay and higher risk of bleeding. Cost calculations
favor the use of argatroban in patients with no history
of HIT necessitating laboratory screening. This should be
investigated further.
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